News • RetInSight

RetInSight is at the forefront of innovative digital health companies developing best-in-class AI software solutions for healthcare applications. As a result, RetInSight is constantly on the move. Every day we take steps that bring our AI solutions closer to eye care professionals, patients and payors. Here you can keep yourself informed of our accomplishments.

Warning: Undefined variable $page in /home/.sites/598/site4080856/web/wp-content/themes/retins24/parts/articlepreview.php on line 16 Warning: Attempt to read property "ID" on null in /home/.sites/598/site4080856/web/wp-content/themes/retins24/parts/articlepreview.php on line 16

Press Release: Regulatory Approvals for AI-Powered Retinal Disease Monitoring

RetInSight GmbH, a Topcon Healthcare, Inc. company and a global leader in AI-based ophthalmic software, today announced that its Geographic Atrophy (GA) Monitor and Fluid Monitor solutions...

Press Release: Topcon Healthcare Acquires RetInSight to Accelerate AI-Powered Imaging Innovation in Eye Care

La Jolla, CA, May 2, 2025 – Topcon Healthcare, Inc., a leading provider of medical devices and digital healthcare solutions, today announced the acquisition of RetInSight GmbH, a privately...

Press Release: Innovative AI-Powered Imaging: Universitäts-Augenklinik Würzburg Integrates RetInSight Software Into AMD Diagnostics

Vienna, April 29, 2025 – The Universitäts-Augenklinik Würzburg (University Eye Hospital Würzburg) has become the first university clinic in Germany to incorporate RetInSight’s medical...

Press Release: RetInSight Announces Exclusive Distribution Agreement with Kilabs Srl for the Italian Market

Vienna – February 25, 2025 – RetInSight GmbH, a leading developer of AI-powered and MDR-certified medical software solutions for retinal diseases, has entered into an exclusive...

Article in FOCUS Magazin: “The Great Medical Revolution: Faster Diagnoses, Better Therapies – The Opportunities of Artificial Intelligence"

RetInSight is revolutionizing diagnosis and therapy in medicine with AI technology. In ophthalmology, our software enables precise diagnosis of age-related macular degeneration (AMD)...

Press Release: RetInSight and veonet launch comprehensive collaboration to improve AMD care

Vienna, 2024, July 10th – RetInSight, a pioneer in AI-based image analysis of retinal diseases, and veonet, a leading network of ophthalmology care centers in several countries, including...

Press Release: Revolutionising Eye Health: I-SCREEN Project Integrates AI for Early Detection of Age-Related Macular Degeneration

Leading the charge in redefining eye care, the innovative I-SCREEN project is tackling age-related macular degeneration (AMD), the predominant cause of severe vision loss in...

Video

Interview: Artificial Intelligence (AI) in the management of retinal diseases

In this episode of the IEMO VideoPodcast, Prof. Paolo Lanzetta is interviewing Prof. Ursula Schmidt-Erfurth on Artificial Intelligence (AI) and how it will bring about transformative changes...

RetInSight Fluid Monitor: Now available with new progression feature

Elevate nAMD management with precision using the Progression Feature in the RetInSight Fluid Monitor, allowing for enhanced disease monitoring and precise visualization of disease...

Press Release: RetInSight secures the first MDR CE-certification for its AI-based GA Monitor for the management of geographic atrophy

RetInSight, an Austrian company, leading in the field of artificial intelligence (AI)-based image analysis of retinal diseases, announces the launch of the RetInSight GA Monitor.

Video: New tool provides AI-based monitoring of geographic atrophy progression

In this Healio Video Perspective, Ursula Schmidt-Erfurth, MD, speaks about OCT-based artificial intelligence analysis for the management of geographic atrophy, a topic she discussed at the...

Quantifying Fluid in AMD

In Retina Today Stela Vujosevic, MD, Department of Biomedical, Surgical and Dental Sciences, University of Milan and Head, Medical Retina Unit, University Eye Clinic, San Giuseppe Hospital,...

Fluid monitor in neovascular age-related macular degeneration: a case report

In this recent case report, Valentina Sarao, MD, Daniele Veritti, MD and Paolo Lanzetta, MD, of the Department of Medicine-Ophthalmology, University of Udine and Istituto Europeo di...

The RetInSight Fluid Monitor at the 2023 SFO congress

Many thanks to Dr. Pierre-Henry Gabrielle of CHU Dijon Bourgogne for presenting his views on the monitoring of nAMD with the RetInSight Fluid Monitor in a fully occupied room at the congress...

RetInSight nominated for Houskapreis

Thank you to the 2023 Houska Prize Jury for recognising our achievements in the development of OCT-based AI-software for Age-related Macular Degeneration by nominating us in the category...

RetInSight at ARVO 2023

It was good to see you at ARVO 2023 in New Orleans, USA. If you missed the presentations about our algorithms for the monitoring of nAMD ad geographic atrophy, you can find the abstracts by...

Leveraging artificial intelligence in clinical management of nAMD

At this year’s EURETINA in Hamburg, Germany, there were several engaging presentations during the Symposium Session that took place on the Friday, 2nd September on the important topic of...

AI-based fluid activity meter drives breakthrough changes in management of neovascular AMD

Regulatory approval of a novel artificial intelligence-based tool that provides precise measurement of retinal fluid may introduce major paradigm changes in the monitoring of patients with...

Heidelberg Engineering and AI software partners present secure workflow solution for ophthalmic analytics at EURETINA and ESCRS

Heidelberg Engineering is expanding its healthcare IT portfolio with the introduction of Heidelberg AppWay. This latest addition to the company’s ecosystem offers secure access to...

RetInSight Fluid Monitor provides next evolutionary step in monitoring of neovascular age-related macular degeneration

First in class AI-based “fluid activity meter” in nAMD obtains CE Mark

RetInSight receives EU Quality Management System certificate according MDR 2017/745

RetInSight, a leader in AI-assisted retinal biomarker image analysis, has received its EU Quality Management System certificate according MDR 2017/745 on December 13, 2021.

Heidelberg Engineering and RetInSight to offer AI-based OCT fluid quantification solution

Heidelberg Engineering GmbH and RetInSight GmbH intend to interface the RetInSight AI-based fluid monitor application with the Heidelberg Engineering product portfolio, using cloud exchange...

Press Release: Topcon Healthcare to Partner with RetInSight

The Market Leader in OCT & Data Management Joins Forces with AI Expert to Provide Improved Clinical Care. Topcon Healthcare of Oakland, NJ, a leading provider of medical devices and software...